Close Menu

NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing technology to Lonza Pharma & Biotech for use in Lonza's bioproduction products and services and in induced pluripotent stem cells for research applications.

Financial terms of the agreement were not disclosed.

"We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way," ERS CEO Eric Rhodes said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

In Science this week: three studies from the Ruminant Genome Project, and more.